← All trials
NCT04542473
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2020
- Primary completion
- Oct 31, 2023
- Completion date
- Jun 30, 2024
- First posted
- Sep 9, 2020
- Last posted
- Sep 9, 2020
- Enrollment
- 1200
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OxfordLead sponsor
- University of WashingtonCollaborator
- Oregon Health and Science UniversityCollaborator
- University of TorontoCollaborator
- University of OxfordStudy chair
- Kenya Medical Research InstituteCollaborator
- International Center for Diarrheal Disease ResearchCollaborator
- Makerere UniversityCollaborator
- Wellcome TrustCollaborator
- University of AmsterdamCollaborator
- Queen Elizabeth Central Hospital, Blantyre, MalawiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.